Tonix Pharmaceuticals (TNXP) Competitors $15.86 -1.14 (-6.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. STOK, PRTC, SANA, HCWB, RVNC, ZVRA, SION, ABVX, MAZE, and VERVShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Stoke Therapeutics (STOK), PureTech Health (PRTC), Sana Biotechnology (SANA), HCW Biologics (HCWB), Revance Therapeutics (RVNC), Zevra Therapeutics (ZVRA), Sionna Therapeutics (SION), ABIVAX Société Anonyme (ABVX), Maze Therapeutics (MAZE), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Stoke Therapeutics PureTech Health Sana Biotechnology HCW Biologics Revance Therapeutics Zevra Therapeutics Sionna Therapeutics ABIVAX Société Anonyme Maze Therapeutics Verve Therapeutics Stoke Therapeutics (NASDAQ:STOK) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking. Which has more volatility & risk, STOK or TNXP? Stoke Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Do institutionals and insiders hold more shares of STOK or TNXP? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 11.3% of Stoke Therapeutics shares are held by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is STOK or TNXP more profitable? Stoke Therapeutics has a net margin of -629.90% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Stoke Therapeutics' return on equity of -54.45% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Tonix Pharmaceuticals -1,197.86%-163.95%-118.88% Does the MarketBeat Community prefer STOK or TNXP? Tonix Pharmaceuticals received 222 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 76.28% of users gave Stoke Therapeutics an outperform vote while only 60.78% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes11976.28% Underperform Votes3723.72% Tonix PharmaceuticalsOutperform Votes34160.78% Underperform Votes22039.22% Which has higher earnings & valuation, STOK or TNXP? Stoke Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M11.01-$104.70M-$1.68-4.43Tonix Pharmaceuticals$10.09M9.81-$116.66M-$2.54 thousand-0.01 Does the media favor STOK or TNXP? In the previous week, Stoke Therapeutics had 6 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 8 mentions for Stoke Therapeutics and 2 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.86 beat Stoke Therapeutics' score of 0.73 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate STOK or TNXP? Stoke Therapeutics presently has a consensus target price of $24.67, suggesting a potential upside of 231.54%. Tonix Pharmaceuticals has a consensus target price of $585.00, suggesting a potential upside of 3,701.17%. Given Tonix Pharmaceuticals' higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryStoke Therapeutics beats Tonix Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Remove Ads Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.06M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio0.006.7221.6917.68Price / Sales10.11223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book0.005.776.373.94Net Income-$116.66M$142.23M$3.20B$247.45M7 Day Performance-11.21%2.72%1.67%0.48%1 Month Performance5.73%-14.04%-9.49%-7.08%1 Year Performance-96.69%-12.31%9.59%-0.35% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.588 of 5 stars$15.86-6.7%$585.00+3,588.5%-96.4%$102.06M$10.09M0.0050STOKStoke Therapeutics3.2628 of 5 stars$7.47+6.4%$24.67+230.2%-36.5%$403.96M$36.56M-3.56100Analyst RevisionGap DownPRTCPureTech Health2.7989 of 5 stars$16.68+3.2%$45.00+169.8%-33.9%$400.64M$3.33M0.00100Upcoming EarningsShort Interest ↓SANASana Biotechnology2.2361 of 5 stars$1.72-2.3%$10.80+527.9%-80.1%$387.04MN/A-1.23380Gap DownHCWBHCW Biologics0.9322 of 5 stars$8.52-7.2%N/A-87.1%$382.94M$2.57M-8.5240Gap DownRVNCRevance Therapeutics2.0258 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500ZVRAZevra Therapeutics2.4255 of 5 stars$7.00+1.4%$22.29+218.4%+45.5%$378.81M$23.61M-3.5520SIONSionna TherapeuticsN/A$8.54+8.5%$38.50+350.8%N/A$376.82MN/A0.0035ABVXABIVAX Société Anonyme2.1614 of 5 stars$5.94-0.5%$38.00+539.7%-58.8%$376.71MN/A0.0061Short Interest ↑Gap DownMAZEMaze TherapeuticsN/A$8.56+9.3%$25.67+199.8%N/A$374.89M$167.50M0.00121Positive NewsGap UpVERVVerve Therapeutics2.9256 of 5 stars$4.13+26.7%$20.67+400.4%-32.0%$366.73M$32.33M-1.68110Analyst ForecastOptions VolumeNews CoverageGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Stoke Therapeutics Alternatives PureTech Health Alternatives Sana Biotechnology Alternatives HCW Biologics Alternatives Revance Therapeutics Alternatives Zevra Therapeutics Alternatives Sionna Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Maze Therapeutics Alternatives Verve Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNXP Stock Free TNXP Stock Alerts